København, 2014-08-18 07:57 CEST (GLOBE NEWSWIRE) -- København, 18. august 2014 – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX København: ZEAL) offentliggør sin delårsrapport for 1. halvår 2014 på torsdag 21. august, hvilket er i overensstemmelse med selskabets finanskalender.
Telefonkonference – Den 21. august 2014, kl. 14.00
På dagen for offentliggørelse af rapporten afholder Zealand kl. 14 en telefonkonference, hvor delårsresultatet vil blive præsenteret sammen med en opdatering på status og udsigter for selskabets primære produkter. Herefter vil der være mulighed for at stille spørgsmål. Deltagere fra Zealands side vil være adm. direktør David Solomon, økonomidirektør Mats Blom og Hanne Leth Hillman, Vice President og Chef for IR og Corporate Communications.
Telefonkonferencen afholdes på engelsk, og deltagelse opnås via følgende nummer:
32 72 80 18
Telefonkonferencen inklusiv en tilhørende slide-præsentation kan følges direkte via audiocast (lydspor) fra følgende link: http://www.media-server.com/m/p/y9zpu4uq. Audiocastet kan også tilgås fra investorsektionen af Zealands hjemmeside (www.zealandpharma.com). Deltagere i audiocastet anbefales at registrere sig ca. 10 min. før, telefonkonferencen starter.
En båndet gengivelse af begivenheden vil efterfølgende være tilgængelig på ZealandAn on-demand version of the audio cast will also be available on the website following the call.
***
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: hlh@zealandpharma.com
Zealand Pharma
Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and a mature portfolio of therapeutic products, which are all based on internal inventions. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, marketed as Lyxumia® under a license agreement with Sanofi. Lyxumia® is approved in several countries globally, including Europe and Japan. In the US, submission of an NDA is expected in 2015, after completion of a cardiovascular outcome study, ELIXA. A once-daily single injection combination of Lyxumia® and Lantus® (LixiLan) is in Phase III development by Sanofi with planned first regulatory filing as early as at the end of 2015.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has two collaborations with Boehringer Ingelheim in diabetes/obesity and cardio-metabolic diseases, one with Lilly in diabetes and obesity, one with Helsinn Healthcare in chemotherapy induced diarrhea and a license agreement with AbbVie in acute kidney injury.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
